[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"respiratory-infection-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:respiratory-infection-virus":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,81,112,142],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":31,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100641007","phase-4-thrive---trial-of-passive-humoral-rsv-immunity-for-value-and-effectiveness-100641007",false,"NCT07578298","THRIVE - Trial of Passive Humoral RSV Immunity for Value and Effectiveness","Passive Immunisation With RSV-specific Monoclonal Antibody (RSV-SMA) to Prevent RSV Respiratory Infections Among Aboriginal and Torres Strait Islander Children in the Northern Territory: a Pragmatic Randomised Controlled Trial.","THRIVE","Inclusion Criteria:\n\n1. Aboriginal and\u002For Torres Strait Islander infant ≥ 6 calendar months old and \\\u003C 9 calendar months old.\n2. Parent\u002Fcaregiver is willing for their infant to participate in the study and informed consent for the infant's participation in the study has been given.\n3. Parent\u002Fcaregiver is willing to comply with all study procedures outlined in the protocol, including review of maternal\u002F infant immunisation records, electronic medical records and public health notifications, for the duration of the study.\n\nExclusion Criteria:\n\n1. Infants with a contra-indication to RSV-SMA per the Australian Immunisation Handbook (i.e. anaphylaxis to a prior dose).\n2. Infants who have received a prior dose of RSV-SMA at ≥ 3 calendar months old.\n3. Previously enrolled in this trial.\n\nTemporary Exclusion Criteria\n\n1. Infants who have received a prior dose of RSV-SMA between ≥ 1 calendar months old and \\\u003C 3 calendar months old will be excluded until at least 150 days have passed since their most recent dose. Randomisation can be delayed until participants meet this criterion.\n2. Acute illness at the time of assessment (e.g. fever ≥ 38.5°C, acute respiratory or other infection as determined by trained and delegated study staff) is temporarily excluded until they are recovered and\u002For symptom-free for ≥ 24 hours.",true,"ALL","6 Months","9 Months",{"count":22,"type":23},1000,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","RSV is a leading cause of severe respiratory illness and hospitalisation for young children, with particularly high rates of RSV respiratory infection observed amongst Aboriginal and Torres Strait Islander children living in Australia's Northern Territory. The goal of this clinical trial is to evaluate whether routinely administering a single dose of respiratory syncytial virus (RSV)-specific monoclonal antibody, nirsevimab, from 6 months old, provides protection against RSV infections for Aboriginal and Torres Strait Islander children throughout in the first and second year of life.\n\nIn this study, participants will be randomly assigned to receive either a single dose of intra-muscular RSV-specific monoclonal antibody, nirsevimab, or standard care (no RSV-specific monoclonal antibody). The primary objective is to determine whether administration ofRSV-specific monoclonal antibody, nirsevimab reduces the occurrence of RSV infection over the subsequent 12 months. Secondary objectives include assessing whether nirsevimab reduces RSV-related hospital attendances, as well as respiratory and all-cause hospitalisations, over the following 6 and 12 months. An assessment of cost-effectiveness will also be undertaken.\n\nParticipants will receive the study intervention at 6 months of age (+90 days). Follow-up will be conducted through passive surveillance using electronic medical records and public health notification systems to capture relevant health outcomes.",[29,30],"Respiratory Syncytial Virus (RSV)","Respiratory Infection Virus",[29,32,33,34,35],"bayesian adaptive","pragmatic clinical trial","Aboriginal and Torres Strait Islander","infants","NOT_YET_RECRUITING","2026-05-05",{"date":39,"type":40},"2026-05-11","ACTUAL",{"date":42,"type":23},"2026-05-15",{"date":44,"type":23},"2030-12-31",{"name":46,"class":47},"Menzies School of Health Research","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":54,"acronym":4,"eligibilityCriteria":55,"healthyVolunteers":11,"sex":18,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":24,"phases":59,"briefSummary":61,"conditions":62,"keywords":65,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":48},"100632691","noseguard-for-prevention-of-respiratory-infections-in-real-world-use-100632691","NCT07516977","Noseguard for Prevention of Respiratory Infections in Real-World Use","A Clinical Study to Evaluate the Effectiveness of Combined Use of Two Nasal Protective Medical Devices (Noseguard and Noseguard Night) for Reducing Respiratory Infection Rates and Assessing Usability","Inclusion Criteria:\n\n* Adults aged ≥19 years\n* Able to provide informed consent\n\nExclusion Criteria:\n\n* Hypersensitivity to device components\n* Current COVID-19 or influenza infection\n* Severe nasal disease\n* Pregnant or breastfeeding women","19 Years",{"count":58,"type":23},2000,[60],"NA","This study is a prospective clinical study to evaluate the effectiveness of combined use of two nasal protective medical devices (Noseguard and Noseguard Night) in reducing respiratory infection rates, including COVID-19 and influenza, in real-world conditions.\n\nThe study will also assess usability, satisfaction, and safety using electronic patient-reported outcomes (ePRO).",[30,63,64],"COVID-19","Influenza",[66,67,68,69,70],"Nasal Spray","Medical Device","Infection prevention","ePRO","Real-World","2026-04-01",{"date":73,"type":40},"2026-04-08",{"date":75,"type":23},"2026-04-20",{"date":77,"type":23},"2026-12-31",{"name":79,"class":80},"Daewoong Pharmaceutical Co. LTD.","INDUSTRY",{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":87,"eligibilityCriteria":88,"healthyVolunteers":17,"sex":18,"minAge":89,"maxAge":4,"enrollmentInfo":90,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":93,"conditions":94,"keywords":96,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":103,"lastUpdatePostDateStruct":104,"startDateStruct":106,"completionDateStruct":108,"leadSponsor":110,"locationsCount":48},"100610599","cohort-study-of-arbovirus-and-other-emerging-virus-infections-in-fiji-aevi-fiji-cohort-100610599","NCT07229677","Cohort Study of Arbovirus and Other Emerging Virus Infections in Fiji: AEVI-Fiji Cohort.","The AEVI-Fiji Cohort Study: a Longitudinal Study Assessing the Transmission Risk and Dynamics of Mosquito-borne and Respiratory Viruses in Fiji.","AEVI-Fiji","Inclusion Criteria:\n\n* Individuals aged 6 years and older who reside in the Central Division of Fiji\n* Have lived in the selected household for at least six months at the time of enrollment\n\nExclusion Criteria:\n\n* Pregnant women;\n* Women in labor, or breastfeeding mothers;\n* Individuals deprived of liberty by judicial or administrative decision;\n* Individuals under psychiatric care or admitted to a health or social care facility for purposes other than participation in the study;\n* Adults under legal protection or unable to provide informed consent;\n* Homeless individuals;\n* Individuals with severe disabilities preventing mobility;\n* Individuals unable to understand or complete the study questionnaire","6 Years",{"count":91,"type":23},910,"OBSERVATIONAL","Background: Fiji, an archipelago in the South Pacific comprising 332 islands distributed among 4 health administrative divisions (Central, Western, Eastern, Northern), is particularly vulnerable to the (re-)emergence of arboviruses and respiratory viruses due to its sub-tropical climate, the presence of several mosquito vector species, and connections with many countries in the Pacific, Asia and North America. Over the past decades, the epidemiological landscape of arboviruses has shifted from the sequential circulation of each of the four dengue virus (DENV) serotypes to the emergence of Zika virus (ZIKV) and chikungunya virus (CHIKV), concomitantly to the concurrent circulation of multiple DENV serotypes. The emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in 2020 significantly challenged Fiji's healthcare system, with the Delta variant alone accounting for approximately 700 deaths, while other respiratory viruses, such as influenza A and B, cause seasonal outbreaks. Despite these threats, comprehensive and up-to-date seroprevalence data remain scarce, limiting the capacity to inform and adapt public health policies.\n\nMethods: The cohort study of Arbovirus and other Emerging Virus Infections in Fiji (AEVI-Fiji cohort study) aims to estimate the prevalence of several arboviruses and respiratory viruses, track the evolution of individual immunity, and analyse transmission dynamics of these viruses within the Fijian population. This longitudinal study will span 38 months and will include about 900 willing participants aged six years and older, recruited from at least 210 households randomly selected across the Central Division. Four visits will be conducted 12 months apart in each household. During each visit, participants will complete a questionnaire capturing their demographic characteristics and history of infections with major arboviruses and respiratory viruses and will provide a blood sample for serological analysis. During the whole study period, participants with a suspected acute infection by an arbovirus or respiratory virus will be screened.\n\nDiscussion: For the first time in Fiji, the AEVI-Fiji cohort study will generate longitudinal data to explore the determinants of both arbovirus and respiratory virus infections. The findings are expected to guide targeted public health strategies and enhance preparedness for future infectious disease threats in Fiji and the broader Oceania region.",[95,30],"Arbovirus Infections",[97,98,99,100,101],"Seroprevalence","Longitudinal cohort","Respiratory viruses","Arboviruses","Fiji Islands","RECRUITING","2025-11-24",{"date":105,"type":40},"2025-12-01",{"date":107,"type":40},"2025-10-23",{"date":109,"type":23},"2028-12-31",{"name":111,"class":47},"Fiji National University",{"id":113,"slug":114,"hasResults":11,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":118,"eligibilityCriteria":119,"healthyVolunteers":17,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":120,"targetDuration":122,"studyType":92,"phases":4,"briefSummary":123,"conditions":124,"keywords":128,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":132,"lastUpdatePostDateStruct":133,"startDateStruct":135,"completionDateStruct":137,"leadSponsor":139,"locationsCount":141},"100604284","preparedness-through-respiratory-virus-epidemiology-and-community-engagement-100604284","NCT07147517","Preparedness Through Respiratory Virus Epidemiology and Community Engagement","PREVENT: Preparedness Through Respiratory Virus Epidemiology and Community Engagement","PREVENT","Community Testing Component:\n\nInclusion:\n\n\\- All community members are able to participate in the community testing component.\n\nExclusion:\n\n\\- There is no exclusion criteria and participants will not be excluded based on pregnancy status or age.\n\nFor Component A:\n\nInclusion:\n\n* All ages\n* AND Lives in service area of a recruitment center (i.e., within range of courier pick up)\n* AND Plans to remain living in a recruitment area for the next 2 years.\n\nExclusion:\n\n* Inability to communicate in a language in which consent forms, materials, etc. are available\n* OR Incarcerated\n* OR Living in a congregate setting (e.g., assisted living, nursing home, university dormitories with shared bathroom and communal eating facilities)\n* OR Unable\u002Funwilling to participate in planned data and specimen collections\n* OR Unable to comply with study procedures, as determined by study investigators\n* OR Participation in clinical trials of investigational agents for respiratory viral infections during the three months prior to enrollment and for the duration of the study.\n\nFor Component B:\n\nInclusion:\n\nIndex case:\n\n* Detection of priority respiratory pathogen via laboratory or point-of-care test on the day of eligibility screening or in the previous 5 days, AND\n* Lives in service area of a recruitment center (i.e., within range of courier pick up), AND\n* Lives in a household with ≥1 other person and plans to remain in the household for at least the duration of specimen collection (i.e., 14 days), AND\n* Has not been hospitalized since the date of symptom onset.\n\nHousehold contacts:\n\n* Routinely sleep in the same household as index case and slept in household ≥1 night in the 7 days before index case symptom onset, AND\n* Plan to remain in the household for at least the duration of specimen collection (i.e., 14 days).\n\nHousehold:\n\n* There is ≥1 non-ill household member (i.e., asymptomatic and has not tested positive for the virus of the index case) on the day of eligibility screening or in the previous 5 days,\n* AND all symptomatic persons in the household had a symptom or diagnosis onset date on the day of eligibility screening or in the previous 5 days.\n\nExclusion:\n\nIndex case:\n\n* Lives in a congregate setting (e.g., assisted living, nursing home, university dormitories with shared bathroom and communal eating facilities)\n* Meet any A1 exclusion criteria\n\nHousehold contacts:\n\n* Has been hospitalized any time since date of primary case symptom onset\n* Meets any A1 exclusion criteria\n\nHousehold:\n\n* The enrollment visit occurs \\>6 days after the first symptom onset of primary case\n* The primary case in the household is not enrolled\n* The primary case has been hospitalized any time after the date of symptom onset",{"count":121,"type":23},25000,"5 Years","The CHARM network will be established through three primary institutions-Beth Israel Deaconess Medical Center (BIDMC), the University of California San Diego (UCSD), and the University of Washington (UW)-along with their subcontracting institutions. At UCSD and partner sites, the CHARM network will be implemented via the PREVENT project. All PREVENT participants will be consented in to Component A0 (Community Testing) and a subset of A0 participants will be invited to participate and will be consented into the other components: Component A (Ongoing Testing); Component A Sub-study (Immunology); Component B (Household Transmission).\n\nComponent A0 participants (Community testing) will be members of the community who are interested in accessing testing for respiratory infections and will be asked to provide limited information that will then be used for screening for study Components A and\u002For B.\n\nParticipants in Component A (Ongoing Testing ) will undergo weekly symptom screening. If they report symptoms, they will be asked to provide a nasal swab and complete illness questionnaires on the day they report symptoms (Day 0) and again on Days 7 and 14. Participants in Component A Sub-study (Immunology) will provide blood and saliva\u002Fnasal fluid samples twice a year, as well as before and after infection and\u002For immunization against priority pathogens.\n\nParticipants in Component B (Household Transmission) will complete daily symptom questionnaires and nasal swabs for 14 days following enrollment, regardless of symptoms. Those who are symptomatic at enrollment will also complete retrospective daily diaries from symptom onset to the enrollment date. Additionally, they provide blood and\u002For saliva\u002Fnasal fluid samples at enrollment and again 28 days later.\n\nFor all Components, UCSD will provide PCR test results for SARS-CoV-2, Influenza A\u002FB, and RSV for nasal swab samples.",[30,125,126,127],"COVID -19","RSV","FLU",[129,130,131],"respiratory pathogen testing","vending machine","implementation","2025-10-31",{"date":134,"type":40},"2025-11-04",{"date":136,"type":40},"2025-10-08",{"date":138,"type":23},"2030-10-30",{"name":140,"class":47},"University of California, San Diego",2,{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":148,"eligibilityCriteria":149,"healthyVolunteers":11,"sex":18,"minAge":150,"maxAge":4,"enrollmentInfo":151,"targetDuration":4,"studyType":92,"phases":4,"briefSummary":153,"conditions":154,"keywords":158,"overallStatus":102,"whyStopped":4,"lastUpdateSubmitDate":164,"lastUpdatePostDateStruct":165,"startDateStruct":167,"completionDateStruct":169,"leadSponsor":171,"locationsCount":48},"100564189","exploring-how-viral-infections-affect-people-with-chronic-lung-disease-100564189","NCT06625944","Exploring How Viral Infections Affect People With Chronic Lung Disease","Prospective Cohort Study to Understand Impact of Viral Infection in Chronic Lung Disease","PRIVILEGE","Inclusion Criteria:\n\n* Adults with a physician confirmed diagnosis of chronic airway disease (e.g. COPD and bronchiectasis) according to established diagnostic criteria.\n\nAND\n\n\\- Prior history of exacerbation within last year (defined as requiring antibiotic and\u002For corticosteroids).\n\nExclusion Criteria:\n\n* Inability to complete daily symptom diaries and\u002For attend for clinical assessments.\n* Exacerbation within 4 weeks of study recruitment and\u002For clinical instability at the time of recruitment.\n* Pregnancy.","18 Years",{"count":152,"type":23},180,"Many people with chronic lung disease have disease flare-ups. It was previously believed that these were mainly caused by bacteria but recent evidence suggests that viruses could be an important trigger. This study will recruit volunteers with chronic lung disease and take samples both when well (at baseline) and during flare-ups (exacerbations) to better understand the role of viruses in triggering exacerbations and also how the immune response is affected. The researchers will follow the volunteers\\' progress for up to two years. Whenever they get unwell they will take some samples (nose swabs, finger prick testing, phlegm sample) and post them to the researchers. Then, they will come in for a visit for more samples (blood tests, further swabs) and a review.",[155,156,157,30],"Bronchiectasis Adult","Bronchiectasis With Acute Exacerbation","COPD (Chronic Obstructive Pulmonary Disease)",[159,160,161,162,163],"Natural Cohort","Prospective","Bronchiectasis","Chronic Lung Disease","COPD","2025-07-09",{"date":166,"type":40},"2025-07-14",{"date":168,"type":40},"2024-11-01",{"date":170,"type":23},"2027-04",{"name":172,"class":47},"Imperial College London"]